Want to see ELTP full AI Analyst Report?
ELTP Stock Chart & Stats
$0.47
>-$0.01(-0.02%)
At close: 4:00 PM EST
$0.47
>-$0.01(-0.02%)
Day’s Range― - ―
52-Week Range$0.33 - $0.74
Previous CloseN/A
Volume475.03K
Average Volume (3M)951.20K
Market Cap
$397.14M
Enterprise Value$382.37M
Total Cash (Recent Filing)$29.80B
Total Debt (Recent Filing)$5.82M
Price to Earnings (P/E)9.5
Beta1.26
Next Earnings
Aug 17, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.03
Shares Outstanding1,077,196,400
10 Day Avg. Volume753,540
30 Day Avg. Volume951,200
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)3.93
Price to Sales (P/S)2.61
P/FCF Ratio0.02
Enterprise Value/Market Cap0.96
Enterprise Value/Revenue2.57
Enterprise Value/Gross Profit5.12
Enterprise Value/Ebitda10.25
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue And Profit SurgeA sustained, large revenue increase driven by multiple own‑label launches demonstrates scaling of Elite's niche generics model. Greater scale and operating leverage underpin more durable gross and operating margins if new products continue to convert through approvals and distribution channels.
Improved Cash Generation And Lower LeverageMaterial cash flow improvement and debt reduction enhance financial flexibility for reinvestment, capacity expansion or M&A. Strong recent FCF conversion reduces refinancing risk and supports sustainable capital allocation even if growth moderates.
Manufacturing Capacity And Pipeline DepthScalable manufacturing and expanded DEA vault/production suites create a durable competitive advantage for controlled‑substance and complex generics. In‑house capacity shortens time to market for approvals, lowers marginal costs, and supports capturing higher market share on successful ANDAs.
Bears Say
Earnings And Cash‑flow VolatilityIrregular earnings and intermittent negative cash flow reduce predictability of free cash flow and complicate long‑term planning. Volatility can hamper consistent reinvestment, increase the cost of capital, and raise execution risk for multi‑year manufacturing or commercial initiatives.
Critical Audit Matter: Chargeback ReserveA critical audit matter signals estimation complexity and potential material adjustments. Persistent uncertainty in chargeback accruals can lead to unexpected reserve increases, margin pressure and higher compliance or administrative costs that erode durable profitability.
Regulatory And IP Timing Risk On Key ANDAsTiming and first‑to‑file disadvantages can delay or reduce exclusivity windows for high‑value generics, materially shifting expected revenue and margin profiles. Lab or BE issues risk regulatory holds that postpone commercialization and weaken projected long‑term growth trajectories.
Elite Pharmaceuticals News
ELTP FAQ
What was Elite Pharmaceuticals’s price range in the past 12 months?
Elite Pharmaceuticals lowest stock price was $0.33 and its highest was $0.74 in the past 12 months.
What is Elite Pharmaceuticals’s market cap?
Elite Pharmaceuticals’s market cap is $397.14M.
When is Elite Pharmaceuticals’s upcoming earnings report date?
Elite Pharmaceuticals’s upcoming earnings report date is Aug 17, 2026 which is in 35 days.
How were Elite Pharmaceuticals’s earnings last quarter?
Elite Pharmaceuticals released its earnings results on Jun 29, 2026. The company reported $0.01 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Elite Pharmaceuticals overvalued?
According to Wall Street analysts Elite Pharmaceuticals’s price is currently Overvalued.
Does Elite Pharmaceuticals pay dividends?
Elite Pharmaceuticals does not currently pay dividends.
What is Elite Pharmaceuticals’s EPS estimate?
Elite Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Elite Pharmaceuticals have?
Elite Pharmaceuticals has 1,077,196,400 shares outstanding.
What happened to Elite Pharmaceuticals’s price movement after its last earnings report?
Elite Pharmaceuticals reported an EPS of $0.01 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -7.595%.
Which hedge fund is a major shareholder of Elite Pharmaceuticals?
Currently, no hedge funds are holding shares in ELTP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Elite Pharmaceuticals Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
ELTP Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 82.0K Shares
Last Quarter.
Last Quarter.
Technicals
SMA
Positive
20 days / 200 days
Momentum
23.00%
12-Months-Change
Fundamentals
Return on Equity
71.43%
Trailing 12-Months
Asset Growth
45.04%
Trailing 12-Months
Company Description
Elite Pharmaceuticals
Elite Pharmaceuticals, Inc. (ELTP) is a specialized pharmaceutical company focused on the creation and manufacturing of generic medications, as well as oral, controlled-release drug formulations. Its business activities are primarily divided into two segments: Abbreviated New Drug Applications (ANDAs) for generic products and New Drug Applications (NDAs) for branded pharmaceuticals. The company's extensive product line includes drugs that it either owns, licenses, or produces through contract manufacturing. This portfolio features a variety of generic and oral-dose pharmaceutical products designed to address diverse medical needs. For instance, it offers Phentermine HCl 37.5mg tablets, marketed under the Adipex-P brand, and Phendimetrazine Tartrate 35mg tablets, known as Bontril, both utilized in bariatric medicine. Its offerings also extend to Naltrexone HCl 50mg tablets (Revia brand) for pain management, and Isradipine 2.5mg and 5mg capsules for cardiovascular conditions. Elite Pharmaceuticals further supplies various strengths of Oxycodone HCl immediate release tablets (5mg, 10mg, 15mg, 20mg, and 30mg) under the Roxycodone brand for pain relief, as well as Trimipramine Maleate Immediate Release antidepressant capsules (Surmontil brand). For central nervous system disorders, the company provides Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, and Amphetamine Sulfate Immediate Release tablets, commonly associated with the Adderall brand. Additionally, its products include Dantrolene Sodium capsules (Dantrium brand) for muscle relaxation, SequestOX (an immediate-release Oxycodone formulation combined with Naltrexone), Loxapine Succinate capsules (Loxapine brand) for antipsychotic treatment, and a combination of Acetaminophen and Codeine Phosphate for managing mild to moderate pain, alongside various antibiotic products. Beyond its own product portfolio, Elite Pharmaceuticals also undertakes contract manufacturing of controlled-release products for external parties, covering therapeutic areas such as pain, allergies, bariatrics, and infections. The company is actively engaged in developing a new generation of opioid products specifically engineered to deter abuse. Established in 1997, Elite Pharmaceuticals, Inc. maintains its corporate headquarters in Northvale, New Jersey.
Technical Analysis
―
SIGA Technologies
―
Amphastar Pharmaceuticals
―
Organogenesis Holdings
―
Aquestive Therapeutics
―
Ownership Overview
0.96% Insiders
<0.01% Other Institutional Investors
99.04% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---











